Amgen beats Street

AMGN reported second quarter EPS of $0.30, two cents better than the Street's estimate of $0.28. Products sales increased 6% to $859 million, up from $807 million in the second quarter last year.

Second quarter combined sales of Epogen epoetin alfa for anemia in dialysis patients and Aranesp next-generation anemia treatment grew 5% to $518 million compared to $493 million in Epogen-only sales in the 2000 quarter. AMGN said that because European approval of Aranesp came late in the second quarter, Aranesp sales did not have a material impact in the quarter. Sales of Neupogen filgrastim increased 10% to $340 million from $310 million in the 2000 period. ...